Therapeutic Agent | Model | Autophagy Inhibition | Response | Reference |
---|---|---|---|---|
Imatinib | Human glioma cell lines | 3-Methyladenine | Decreased cytotoxicity | Shingu et al., 2009 |
Bafilomycin A | Increased cytotoxicity | |||
Imatinib | Human Philadelphia chromosome positive CML cells | Chloroquine | Increased cytotoxicity | Bellodi et al., 2009 |
HDACi/vorinostat | Human colon cancer cells and xenografts | Chloroquine | Increased cytotoxicity | Carew et al., 2010 |
Decreased growth | ||||
HDACi/panobinostat | Human triple negative breast cancer cells and xenografts | Chloroquine | Increased cytotoxicity | Rao et al., 2012 |
Decreased tumor growth | ||||
HDACi/SAHA | Human CML cell lines and primary CML cells | Chloroquine | Increased cytotoxicity | Carew et al., 2007 |
HDACi/valproic acid | Human t(8;21) acute myeloid leukemia cells | Chloroquine | Increased cytotoxicity | Torgersen et al., 2013 |
HSP90i/DMAG | Human multiple myeloma cell lines | 3-Methyladenine | Increased cytotoxicity | Palacios et al., 2010 |
Erlotinib | Human glioblastoma cell lines | Chloroquine | Increased cytotoxicity | Eimer et al., 2011 |
Sorafenib | Human hepatocellular carcinoma cell lines and xenografts | Chloroquine | Increased cytotoxicity and decreased tumor growth | Shi et al., 2011 |
3-Methyladenine | ||||
Sorafenib | Human hepatocellular carcinoma cell lines and xenografts | Chloroquine | Increased cytotoxicity and decreased tumor growth | Shimizu et al., 2012 |
Sunitinib | Rat PC12 cells | Ammonium chloride | Increased cytotoxicity | Ikeda et al., 2013 |
AKTi/AZD5363 | Human prostate cancer cell lines and xenograft | 3-Methyladenine | Increased cytotoxicity and decreased tumor growth | Lamoureux et al., 2013 |
Chloroquine | ||||
Bafilomycin A | ||||
METi/PHA665752 and EMD1214063 | Human gastric adenocarcinoma cell line | 3-Methyladenine | Increased cytotoxicity | Humbert et al., 2013 |
Vandetanib | Human glioblastoma cell lines and xenograft | 3-Methyladenine | Increased cytotoxicity and decreased tumor growth | Shen et al., 2013 |
Chloroquine | ||||
Bevacizumab | Human hepatocellular carcinoma xenografts | Chloroquine | Decreased tumor growth | Guo et al., 2013b |
Bortezomib | Human multiple myeloma cell line (U266) | 3-Methyladenine | Decreased cytotoxicity | Kawaguchi et al., 2011 |
Bafilomycin A | Increased cytotoxicity | |||
Bortezomib | Human hepatocellular carcinoma cell lines and xenografts | Chloroquine | Increased apoptosis | Hui et al., 2012 |
AKTi, AKT inhibitor; AZD5363, (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide; EMD1214063, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile; HDACi, histone deacetylase inhibitor; PHA665752, (2R)-1-[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)pyrrolidine.